SEC Form 4 · accession 0001144204-17-037574
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elliot M Maza
Officer — Interim CEO · Director
Period of report
Jul 18, 2017
Accepted (ET)
Jul 20, 2017 · 8:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $2.69 | Jul 18, 2017 | A | 100,000 | A | Jul 18, 2017 | Jul 18, 2027 | Common Stock | 100,000 | 162,000 | D |
Explanation of responses
- F1The option to purchase up to 100,000 shares of the Issuer's common stock shall vest as follows: (i) the option to purchase up to 50,000 shares of common stock vest on the date of grant and (ii) the balance of the option, or the option to purchase up to 50,000 shares of common stock shall vest quarterly over a two year period, subject to shareholder approval.